title: Impact of being underweight or overweight on factor VIII dosing in hemophilia A patients.
abstract: Since 1981, the number of factor VIII units to infuse into patients with hemophilia A in order to achieve adequate circulating factor VIII levels has been calculated using the formula: [body weight(kg)× desired factor VIII increase(%)]/2, assuming a factor VIII recovery value of 2 for all patients. This study's aim was to evaluate the impact of several morphometric parameters and various coagulation factor concentrates on factor VIII recovery.The analysis included 201 hemophilia A adults (>18 years of age) who were carefully selected from eight pharmacokinetic clinical trials using three recombinant factor VIII concentrates (Advate®, Kogenate® FS, or ReFactoAF®/Xyntha®). Regression tree analysis was used to identify factor VIII recovery predictors. The median factor VIII recovery was 2.16 for all patients. Using regression tree analysis, patients were separated into three groups on the basis of body mass index: below 20.3 kg/m(2), between 20.3 and 29.5 kg/m(2), and 29.6 kg/m(2) or more. Each group had a significantly different median factor VIII recovery (P<0.001): 1.60, 2.14, and 2.70, respectively. The type of coagulation factor concentrate had no influence on recovery in the regression tree. In conclusion, factor VIII dosing should be adapted to underweight and overweight patients, as a factor VIII recovery of 2 does not apply to these patients. Ideal body weight should be considered instead of actual body weight in the dose calculations.
authors: Institute of Health and Society (IRSS), Université Catholique de Louvain, Brussels, Belgium.
authors: Séverine
authors: S
authors: Henrard
authors: Niko
authors: N
authors: Speybroeck
authors: Cedric
authors: C
authors: Hermans
mesh_terms: D000328:Adult; D015992:Body Mass Index; D015331:Cohort Studies; D005169:Factor VIII / Q000008:administration & dosage* / Q000378:metabolism*; D005260:Female; D006467:Hemophilia A / Q000097:blood* / Q000188:drug therapy; D006801:Humans; D008297:Male; D050177:Overweight / Q000097:blood* / Q000188:drug therapy; D013851:Thinness / Q000097:blood* / Q000188:drug therapy; D055815:Young Adult
chemical_list: C078147:F8 protein, human; D005169:Factor VIII
references: Br J Haematol. 1981 Jun;48(2):351-4
references: 6786322
references: Br J Nutr. 1991 Mar;65(2):105-14
references: 2043597
references: Clin Pharmacokinet. 2001;40(11):815-32
references: 11735604
references: Am J Prev Med. 2011 Dec;41(6 Suppl 4):S369-75
references: 22099360
references: Lancet. 2003 May 24;361(9371):1801-9
references: 12781551
references: J Thromb Haemost. 2008 Aug;6(8):1319-26
references: 18503631
references: Int J Public Health. 2012 Feb;57(1):243-6
references: 22015650
references: J Thromb Haemost. 2011 Sep;9(9):1784-90
references: 21729239
references: J Thromb Haemost. 2010 Apr;8(4):730-6
references: 20398185
references: J Clin Epidemiol. 2001 Jun;54(6):603-9
references: 11377121
references: Ther Adv Hematol. 2012 Jun;3(3):165-75
references: 23556123
references: Haemophilia. 2011 Jan;17(1):2-10
references: 20731726